Armata Pharmaceuticals, Inc. — Director's Dealing 2016

Nov 16, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AmpliPhi Biosciences Corp (APHB)
CIK: 0000921114
Period of Report: 2016-11-12

Reporting Person: KIRK RANDAL J (10% Owner)
Reporting Person: INTREXON CORP (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-12	Common Stock	C	428571	—	Acquired	828571	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-12	Series B Preferred Stock	$	C	2142857	Disposed		Common Stock (428571)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	758788	Indirect

Footnotes

F1: On November 12, 2016, NRM VII Holdings I, LLC ("NRM VII Holdings") and the issuer entered into a settlement agreement with respect to the lawsuit filed against the issuer and the members of its Board of Directors relating to the automatic conversion of Series B Convertible Preferred Stock.

F2: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon Corporation. Shares held by Intrexon Corporation may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: In connection with the automatic conversion of Series B Convertible Preferred Stock the shares were automatically converted at a ratio of 1-to-5. Shares of Series B Convertible Preferred Stock had no expiration date.